Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
AbbVie’s upadacitinib aces phase III trial
even climb as high as $5bn at peak if it also shows its worth in follow-up indications like psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.
Latest news
-
ViiV’s two-drug HIV combo backed by CHMP
Sandoz’Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.
-
FDA turns down Celgene’s filing for multiple sclerosis drug
The drug’s second clinical programme in ulcerative colitis is not expected to be affected by the latest regulatory decision. ... of Crohn’s disease candidate GED-0301, and lacklustre data for psoriasis therapy Otezla (apremilast) in ulcerative colitis
-
Shaky mid-stage data won’t halt Celgene’s plans for Otezla
Celgene intends to expand its use into a series of other inflammatory diseases with ulcerative colitis at the head of its list along with Behçet’s disease. ... ulcerative colitis patients who had failed at least on conventional systemic therapy, but
-
AbbVie reports more solid data for would-be psoriasis blockbuster
AbbVie now says it plans to begin pivotal studies in atopic dermatitis, as well as ulcerative colitis and giant cell arteritis before the end of the year.
-
J&J takes option on Theravance’s JAK drug in $1bn deal
TD-1473 has potential treating ulcerative colitis, Crohn’s and IBD patients. Johnson &Johnson is paying $100m upfront for opt-in rights to a JAK inhibitor developed by Theravance, with another ... In the next few years the market is estimated to swell
More from news
Approximately 19 fully matching, plus 102 partially matching documents found.
Latest Intelligence
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
-
Deal Watch January 2017
Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Biosimilars - the same, but different?
The first months of 2015 also saw it approve Remsima and Inflectra for use on the NHS to treat moderately to severely active ulcerative colitis after the failure of conventional therapy.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
AstraZeneca veteran Deborah Hartman joins Avaxia. Will lead the development of AVX-470 in ulcerative colitis. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017. ... Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US.
-
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report. ... Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US.
-
News: Research Partnership launches new patient report - Living with Ulcerative Colitis
News: Research Partnership launches new patient report - Living with Ulcerative Colitis. ... Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016. ... Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe.
-
Lucid reach the shortlist for Communiqué 2016 in SIX categories
The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) online tool. Emerging Leader in Healthcare Communications.
More from PMHub
Approximately 4 fully matching, plus 2 partially matching documents found.
Featured jobs
- Account Manager – Med Comms – London
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
-
Scientific Director
-
Great salary and bebefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Senior Programme Executive
-
Salary TBC
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
Subscribe to our email news alerts
- BenevolentAI raises $115m to fund drug development
- Shire rebuffs Takeda bids, as Allergan bows out
- Abeona Therapeutics names CEO
- Zelluna Immunotherapy appoints chief technology officer
- Spirit Health Group offers new market access consultancy service
- Why heading online for scientific meetings can yield greater HCP engagement
PMHub
CMR
Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...
Latest intelligence
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Quick links
Infographics
